Home / Stock ratings / BEAM

Stock rating · Biological Products, (No Diagnostic Substances)

Beam Therapeutics Inc. (BEAM) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Beam Therapeutics Inc. 43 out of 100 (Promising). Its highest factor score is earnings track record at 88, and its lowest is price momentum at 8.

MELANY ratingRated 2026-11-20

BEAM · composite score

43/100
Promising
Nov 20
Rating date
Live price in the app →
Quality32
Momentum8
Risk-adjusted25
Source basis SEC filings and live market dataDated snapshot

About Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company developing a new class of precision genetic medicines built on its proprietary base editing technology, aiming to deliver lifelong cures for patients with serious diseases.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why BEAM scores 43/100

BEAM's 8 factor scores run from 8 to 88, and 5 of them sit above its composite of 43. Here is how BEAM breaks down.

Valuation66/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

Business quality32/100

Margins, returns on capital, and balance-sheet strength.

Price momentum8/100

Direction and relative strength of the recent share-price trend.

Earnings track record88/100

History of beating or missing estimates, and where estimates are heading.

  • Avg EPS beat +24%
Analyst sentiment67/100

What Wall Street price targets and revisions are signalling.

  • Analyst targets 138% upside
  • Institutional net buying +4.3%
Catalyst setup47/100

Near-term events that could move the stock.

Risk-adjusted profile25/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How BEAM compares

As of November 20, 2026, Beam Therapeutics Inc. ranks 9th of the 10 companies with a MELANY rating page in its SEC industry group (Biological Products, (No Diagnostic Substances)), where the average score is 53.

All stock rating pages.

Key risks for BEAM

  • Operating margin -268%, cash-burn business, dependent on capital markets
  • Negative free cash flow, company consuming cash, not generating it
  • Short interest 39% of float, high volatility risk on news
  • Weak price momentum, trend not yet confirmed, may need more time to set up
  • High beta 2.2, amplifies market drawdowns 1.8x+ in selloffs

Sector and theme context

Beam Therapeutics Inc. sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds BEAM's momentum and catalyst factors above.

BEAM trade plan (Pro)

MELANY has a full position plan for Beam Therapeutics Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates BEAM

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Beam Therapeutics Inc.'s 43/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about BEAM

Is Beam Therapeutics Inc. (BEAM) a buy?

As of 2026-11-20, MELANY rated Beam Therapeutics Inc. Promising with a composite score of 43/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does BEAM rank against similar companies?

As of November 20, 2026, Beam Therapeutics Inc. ranks 9th of the 10 companies with a MELANY rating page in its SEC industry group (Biological Products, (No Diagnostic Substances)), where the average score is 53. Among the other names in the group, the highest scores belong to AMGN (62) and BIIB (60).

Should I buy Beam Therapeutics Inc. stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Beam Therapeutics Inc. (BEAM) Promising with a composite of 43/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the BEAM stock price forecast?

MELANY does not publish price targets or forecasts for BEAM. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 43/100 across eight factors for Beam Therapeutics Inc., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for BEAM as of 2026-11-20: its analyst sentiment factor is 67/100 (Analyst targets 138% upside), and its price momentum factor is 8/100.

Is BEAM stock overvalued or undervalued?

MELANY's valuation factor currently reads 66/100 for Beam Therapeutics Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BEAM's read.

What price should I buy BEAM at?

Rather than chasing the current price, MELANY computes a smart entry zone for BEAM: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying BEAM stock?

The top risks MELANY currently flags for Beam Therapeutics Inc.: Operating margin -268%, cash-burn business, dependent on capital markets; Negative free cash flow, company consuming cash, not generating it; Short interest 39% of float, high volatility risk on news; Weak price momentum, trend not yet confirmed, may need more time to set up; High beta 2.2, amplifies market drawdowns 1.8x+ in selloffs. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Beam Therapeutics Inc. a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 32/100 for Beam Therapeutics Inc., and earnings track record, at 88/100. The 43/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will BEAM stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 8/100 for BEAM right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this BEAM rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores BEAM as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, BEAM included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.